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doi:10.1016/j.jtcvs.2006.03.027ardiopulmonary bypass (CPB) can be used during cardiac surgery to oxy-
genate and subsequently recirculate blood that has been diverted from the
heart and lungs. The practice of CPB has changed—and continues to
hange—dramatically since its advent in the 1950s. Although structured reviews of
he evidence supporting the practice of cardiac surgery have been in the literature for
ore than a decade and continue to be refined in the wake of new and emerging
vidence,E1,E2 additional targeted reviews, focusing on issues such as minimizing
he effect of the inflammatory response or minimizing neurologic injury, are
arranted.E3-E5 Previous attempts, by Edwards and colleaguesE6 and Bartels and
ssociates,E7 at synthesizing the evidence base to support the principles of CPB have
electively reviewed the cardiac surgery literature or focused on unique patient
opulations. Additionally, the development of these reviews has not involved all
embers of the clinical team, most notably the individuals tasked with operating the
PB circuit. This gap in knowledge is in stark contrast with the shared goal of the
ardiac team, namely to improve the conduct of CPB to reduce the patient’s risk of
dverse outcomes caused by cardiac surgery.
Despite a preponderance of evidence supporting key principles of managing safe
nd effective CPB practice, wide variation in the use of technology and techniques
or conducting CPB persists regionally and nationally.E8,E9 Variations in practice
ave previously been shown to be associated with increased costs, lengths of stay,
eurologic injury, and mortality.1-3,E5,E10,E11 This variation might be attributed to
linical uncertainty or institutional or local practice standards. To reduce this
nwanted practice variation, we must provide our clinical colleagues with critically
valuated and evidence-based review for conducting CPB.
What follows is an evidence-based review for conducting safe, patient-centered,
nd effective CPB practice. The authors have graded the level of evidence and
lassified the findings listed below by using the criteria promulgated by the Amer-
can Heart Association and the American College of Cardiology Task Force on
ractice Guidelines (Table 1). The development of these findings evolved from a
tructured MEDLINE search coupled with critical review of the peer-review liter-
ture and debates stemming from presentations at regional and national conferences,
ncluding the Connecticut Society of Perfusion (2004), Outcomes 2004: The Key
est Meeting, New York State Society of Perfusion (2004), 12th Annual Meeting
n Optimization of Blood Management During Surgery (2004), Florida State
ociety of Perfusion (2004), Tennessee State Society of Perfusion (2004), American
cademy of Cardiovascular Perfusion (2005, 2006), and Outcomes 2005: The Key
est Meeting.
The authors, a multidisciplinary group of physicians, epidemiologists, and per-
usionists, seek to develop and share evidence-based reviews for conducting CPB
hrough rigorous, structured, and expert-driven analysis of the peer-reviewed liter-
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2ture. The mission of this group is to promote literature-
upported and evidence-based perfusion practice to improve
atient care and enhance clinical outcomes.
We present this as the first of several documents regard-
ng the development of evidence-based review for conduct-
ng CPB. In this initial document, regarding the develop-
ent of evidence-based findings for CPB, we focus on
eurologic protection, euglycemia, hemodilution, and the
nflammatory response. These findings will be updated to
nsure that they continue to be concurrent with emerging
vidence and relevant to practicing clinicians.
ethods
he initiative to identify the evidence base and develop findings
or perfusion practice evolved from conversations between 2 of the
uthors (KS, DR). Subsequent conversations between these and
ther investigators resulted in the development of our study’s
ethodology.
We chose not to conduct a meta-analysis of the peer-reviewed
iterature, and instead, we adopted a process set forth by the
merican Heart Association and American College of Cardiology
http://www.acc.org/clinical/manual/manual_I.htm) for the devel-
pment of evidence-based reviews of the peer-reviewed literature.
n short, the group agreed to (1) determine and agree to the scope
nd clinical objectives, (2) define and conduct appropriate and
omprehensive literature searches, (3) sort and evaluate the evi-
ence, (4) synthesize and interpret the evidence, (5) write findings
ased on expert interpretation of the evidence, (6) assign classifi-
ation of findings and strength of evidence, and (7) assemble the
ocument. Critical to the success of this project was a detailed and
horough literature search conducted by an expert biomedical
ibrarian (search strategy available by request). Searches were
onducted for each of the agreed-upon topics, and results were
osted on a customized Web site through the National Center for
iotechnology Information (http://www.ncbi.nlm.nih.gov/entrez/).
Expert reviewers accessed the saved searches through this Web
ite and used the criteria set forth by the American Heart Associ-
tion and American College of Cardiology to develop the findings
able 1. Methodologies and policies from the American Co
ractice Guidelines
lassification of recommendations
lass I: Conditions for which there is evidence, general agreeme
or both that a given procedure or treatment is useful and
effective
lass II: Procedure-treatment should be performed-administered
lass IIA: Additional studies with focused objectives needed
lass IIB: Additional studies with broad objectives needed;
additional registry data would be helpful
lass III: Procedure-treatment should not be performed-administe
because it is not helpful and might be harmful
dapted from Eagle KA, Guyton RA, Davidoff R, et al, ACC/AHA 2004 Guidel
ollege of Cardiology/American Heart Association Task Force on Practice G
raft Surgery); 2004.ontained herein. The level and class of evidence was applied to p
84 The Journal of Thoracic and Cardiovascular Surgery ● Auguach finding by using a structured literature search of nonanimal
tudies referenced in MEDLINE. Although animal studies might
e referenced within this document, they were not used in the
evelopment of the findings. Findings were shared with all coin-
estigators and reflect input gathered from presentations at re-
ional, national, and international conferences. Findings for each
ection were written based on the guidance set forth by the Amer-
can Heart Association and American College of Cardiology.
eurologic Protection
ompared with a decade ago, greater numbers of patients of
ncreasing age are surviving more extensive operations,
ith a shorter duration of hospitalization.E12 Despite these
dvances, a number of fundamental clinical issues continue
o be managed by clinical routine, rather than reflecting an
ptimized CPB strategy for reduction of central nervous
ystem injury. This clinical routine is likely to result in
issed opportunities for optimizing care based on the pa-
ient’s risk of an adverse neurologic outcome.
H Management
f fundamental importance in the care of patients undergo-
ng CPB is acid-base status, specifically related to pH man-
gement and CO2 regulation. Since the initial hypothesis
hat alpha-stat pH management would be associated with
mproved outcomes,4 there have been at least 3 independent
rospective randomized trials demonstrating improved neu-
ologic and neuropsychologic outcomes associated with al-
ha-stat pH management in adult patients undergoing mod-
rately hypothermic CPB.1,5,6 Alpha-stat blood gas
anagement preserves cerebral blood flow–metabolism
oupling such that hypothermic-induced decreases in met-
bolic rate are accompanied by proportionate decreases in
erebral blood flow.4 The authors do recognize there might
e specific circumstances, such as chronic hypercapnia, that
ight require a modification of this approach to preserve
of Cardiology/American Heart Association Task Force on
Level of evidence
Level A: Data derived from multiple randomized clinical trials
Level B: Data derived from a single randomized trial or
nonrandomized studies
Level C: Consensus opinion of experts
date for Coronary Artery Bypass Graft Surgery: A Report of the American
ines (Committee to Update the 1999 Guidelines for Coronary Artery Bypassllege
nt,
red
ine Up
uidelreoperative physiologic levels of PCO2.
st 2006
H
A
o
a
u
b
A
e
p
t
t
l
a
s
B
o
n
c
b
f
m
e
i
s
a
C
p
n
w
p
i
p
p
t
t
r
m
t
b
m
r
r
p
C
t
r
v
S
i
m
s
c
v
t
c
a
e
s
t
b
a
a
i
h
w
d
T
a
l
t
t
l
o
w
T
r
c
w
a
n
a
s
u
r
b
r
g
T
g
a
t
p
e
m
P
i
m
Shann et al Cardiopulmonary Support and PhysiologypH Management
The clinical team should manage adult patients
undergoing moderate hypothermic CPB with alpha-
stat pH management. (Class I, Level A)
yperthermia
s reported by Pugsley and coworkers,7 a patient’s risk
f neuropsychologic injury in the setting of coronary
rtery bypass grafting (CABG) surgery is in part attrib-
ted to the quantity of microemboli delivered to the
rain. As reported by van der Linden and Casimir-
hn,E13 a high percentage of emboli occur during the
arly and late phases of cardiac surgery. At the time when
atients are most likely to experience an ischemic event,
hey are typically perfused at warmer temperatures.
Most of the evidence documenting poorer outcomes in
he setting of cerebral hyperthermia comes from the stroke
iterature. Hajat and colleaguesE14 previously identified an
ssociation between cerebral hyperthermia in the setting of
troke with increased morbidity and mortality. Ginsberg and
ustoE15 elucidated the effect of hyperthermia in the setting
f cerebral ischemia, identifying some of these mecha-
isms: (1) increased release of neurotransmitters, (2) in-
reased free radical production, (3) breakdown of the blood-
rain barrier, (4) increased ischemic depolarizations in the
ocal ischemic penumbra, (5) impaired recovery of energy
etabolism and inhibition of protein kinases, and (6) wors-
ning of cytoskeletal proteolysis. Hajat and colleagues,E14
n a meta-analysis of the effects of hyperthermia in the
etting of stroke, reported increased morbidity and mortality
mong patients experiencing hyperthermia. In the setting of
ABG surgery, Grocott and associates8 similarly found
ostoperative hyperthermia to be associated with greater
europsychologic dysfunction. Similarly, Grigore and co-
orkers2 found greater neuropsychologic dysfunction in
atients randomized to a faster rather than slower rewarm-
ng rate in the setting of CABG surgery. Interestingly,
atients rewarmed at a faster rate were exposed to higher
eak temperatures and a higher mean temperature of greater
han 37°C than patients rewarmed slower with lower peak
emperatures. Monitoring for and aggressively treating ce-
ebral hyperthermia thus likely offers an opportunity to
inimize the exacerbation of neurologic injury in the set-
ing of CABG surgery.
Hypothermia is widely used during CPB to protect the
rain and other vital organs by reducing the oxygen require-
ents of affected tissues. Hypothermic CPB, however, as
eported by Insler and colleagues,E16 requires a period of
ewarming to avoid the adverse outcomes associated with
ostoperative hypothermia. Contemporary management of
PB, which does not emphasize aggressive monitoring of
emperatures, therefore potentially exposes the brain to pe-
iods of hyperthermia, as identified by Nathan and La-
alleeE17 and Cook and associatesE18 separately. Although i
The Journal of Thoracictone and coworkersE19 reported nasopharyngeal monitor-
ng to match well to brain temperature compared with other
onitoring sites, Cook and colleagues,E18 Grocott and as-
ociates,E20 Kaukuntla and colleagues,9 and Johnson and
oworkersE21 have noted that it might underestimate jugular
enous temperatures and thereby expose the brain to unin-
ended hyperthermia. As documented by Kaukuntla and
olleagues,9 without monitoring and attentive management,
rterial inflow temperatures of the CPB circuit will likely
xceed corporeal temperatures and expose the brain to sub-
equent hyperthermia. It would therefore be advantageous
o at least monitor arterial inflow temperature. Caution must
e encouraged here because recent work by Salah and
ssociatesE22 and Newland and coworkersE23 has suggested
n underestimation of arterial inflow temperature while us-
ng conventional coupled temperature-monitoring devices.
Ten randomized controlled trials and 2 prospective co-
ort studies have evaluated neurologic outcomes associated
ith temperature management during CPB. Of the 10 ran-
omized controlled trials, 6 (McLean and colleagues,E24
he Warm Heart Investigators,E25 Engelman and associ-
tes,E26 Grigore and coworkers,E27 Plourde and col-
eagues,E28 and Birdi and associatesE29) concluded that
here was no difference between normothermic and hypo-
hermic CPB, 3 (Martin and coworkers,E30 Mora and col-
eagues,E31 and Regragui and associatesE32) reported poorer
utcomes with normothermic CPB, and 1 (Grimm and co-
orkersE33) found poorer outcomes with hypothermic CPB.
hree nonrandomized studies reported conflicting findings
egarding temperature management and neurologic out-
omes, with 1 (Gaudino and colleaguesE34) concluding
orse outcome with normothermic CPB and 2 (Singh and
ssociatesE35 and Christenson and coworkersE36) showing
o statistical difference. Differences in these findings likely
re attributed to heterogeneity in study design, lack of
tandardized temperature-monitoring sites, and potentially
nrecognized cerebral hyperthermia among study patients,
egardless of temperature management strategy. The study
y Nathan and colleagues10 is noteworthy in that the group
andomized to separate from bypass at 34°C (hypothermic
roup) most likely avoided any transient hyperthermia.
hey found a reduction in neuropsychologic deficits in this
roup compared with the group rewarmed to 37°C, without
concomitant increase in morbidity and mortality.
The measurement and tracking of perioperative hyper-
hermia is essential for neurologic protection. Cerebral tem-
eratures exceeding 37°C might expose patients to unnec-
ssary neurologic risk. During CPB, reliable and accurate
easurement of arterial inflow temperatures is imperative.
reventing hyperthermia and subsequent risk of neurologic
njury in this setting might occur through reliable measure-
ent and strict avoidance of perfusion temperatures exceed-ng 37°C.
and Cardiovascular Surgery ● Volume 132, Number 2 285
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2Avoidance of Hyperthermia
Limiting arterial line temperature to 37°C might be
useful for avoiding cerebral hyperthermia. (Class IIa,
Level B)
“Coupled temperature” ports for all oxygenators
should be checked for accuracy and calibrated.
inimizing Return of Pericardial Suction Blood
s noted separately by Caguin and Carter,11 Clark and
ssociates,E38 and Siderys and coworkers,E39 reinfusion of
ardiotomy suction blood exposed to pericardial and medi-
stinal surfaces in patients undergoing CPB is associated
ith postoperative neurologic injury, attributed in part to
ncreased levels of hemolysis and fat in scavenged blood.
rooker and colleaguesE40 identified the association be-
ween cerebral lipid microemboli after CPB with the rein-
usion of cardiotomy suction blood in a canine model.
dditionally, Appelblad and Engstrom,E41 Kaza and asso-
iates,12 Jewell and coworkers,13 and de Vries and col-
eaguesE42 identified pericardial suction blood as the pri-
ary source of fat emboli during CPB. De Hann and
ssociates14 demonstrated that reinfusion of pericardial suc-
ion blood exacerbated activation of markers of coagulation
nd fibrinolysis and resulted in increased blood loss.
panier and coworkersE43 documented increased endotoxin
evels with the reinfusion of pericardial suction blood dur-
ng CPB, whereas research conducted by Chung and col-
eagues,15 Johnell and associates,E44 and Weerwind and
oworkersE45 reported the following sequelae: thrombin
eneration and activation of the coagulation, fibrinolytic,
nd inflammatory pathways.
To reduce systemic inflammatory response and exposure
o fat emboli, techniques to minimize shed mediastinal
lood through improved intraoperative hemostasis should
e advocated, and where possible, reinfusion of pericardial
uction blood should be avoided. Secondary filtration of
ericardial suction blood, as well as treatment with a blood
ell processor with or without additional filtration before
eturn to the extracorporeal circuit, has resulted in reduced
einfusion of fat emboli, as noted by Kaza and associates,12
ewell and coworkers,13 de Vries and colleagues,E42 and
incaid and associates.E46
Return of Pericardial Suction Blood
Direct reinfusion to the CPB circuit of unprocessed
blood exposed to pericardial and mediastinal surfaces
should be avoided. (Class I, Level B)
Blood cell processing and secondary filtration can
be considered to decrease the deleterious effects of
reinfused shed blood. (Class IIb, Level B)
ortic Assessment
s noted by Likosky and associates,E47 among others, ce-
ebral atheroemboli account for the majority of type I
stroke) outcomes after CABG surgery, with noncalcific f
86 The Journal of Thoracic and Cardiovascular Surgery ● Augulaque likely the greatest contributor of these emboli.
avila-Roman and colleagues16 reported that noncalcific
laque, unfortunately, is least likely to be identified by
ntraoperative surgical palpation of the aorta before instru-
entation. Blauth and coworkersE48 and Davila-
oman and associatesE49 have shown that advanced age,
iabetes mellitus, and vascular disease, all conditions that
re well-known risk factors for perioperative stroke, are also
redictors of advanced aortic atherosclerosis and attendant
ystemic atheroemboli. Mizuno and colleaguesE50 and
avila-Roman and associatesE49 identified significant ath-
rosclerosis (defined as intimal thickening 5 mm in the
ortic arch), present in up to 20% of patients undergoing
ABG, to be associated with an increased risk of stroke
fter CABG, presumably through an embolic mechanism, as
uggested by Djaiani and colleagues.E51 As reported by
avila-Roman and colleagues,16 epiaortic ultrasonography
s significantly more sensitive than transesophageal echo-
ardiography (TEE) for identification of atherosclerosis of
he ascending aorta, whereas Sylvris and associates17 and
oyse and coworkers18 have identified both ultrasono-
raphic techniques to be superior to palpation. Epiaortic
ltrasonography and TEE provide complementary informa-
ion regarding thoracic aortic atherosclerosis. Many reports
Davila-Roman and associates,E49 Trehan and colleagues,19
old and coworkers,E52 and Mackensen and associates20)
ave highlighted a protective effect, in terms of prevention
f atheroembolic complications, with the modification of
urgical technique on the basis of results of intraoperative
piaortic ultrasonography and TEE in elderly patients un-
ergoing cardiac procedures. As reported by Gold and co-
orkers,E52 Trehan and colleagues,19 Ribakove and associ-
tes,E53 and Baribeau and coworkers,E54 epiaortic
ltrasonography and TEE might facilitate the reduction of
eurologic injury through the identification of areas free
rom atherosclerosis for aortic cannulation, avoidance of the
scending aorta entirely through femoral or axillary artery
ites, or use of an off-pump technique.
Aortic Assessment
In patients undergoing CPB at increased risk of
adverse neurologic events, strong consideration
should be given to intraoperative TEE or epiaortic
ultrasonographic scanning of the aorta: (1) to detect
nonpalpable plaque (Class I, Level B) and (2) for
reduction of cerebral emboli (Class IIa, Level B).
rterial Line Filtration
he presence of microemboli (gaseous or particulate) and
oreign material in the CPB circuit and subsequent delivery
o the patient through the arterial line has resulted in the
ncorporation of arterial filters into CPB circuits. Although
n vitro and in vivo studies by Taylor and coworkersE55 and
oop and associates,21 respectively, have provided evidenceor benefits associated with the inclusion of these filters into
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Shann et al Cardiopulmonary Support and Physiologyhe arterial line, their routine use in the CPB circuit is not
niversal.E56
Pugsley and colleagues7 and Padayachee and cowork-
rs22 demonstrated a reduction in embolic load delivered to
he brain with the inclusion of arterial line filters, whereas
ellman and associates23 similarly demonstrated a reduction
n emboli distal to the arterial line filter. Padayachee and
oworkers22 additionally demonstrated an advantage with
5- versus 40-m filters in removing gaseous microemboli.
Most studies reporting on the benefits of filtration were
erformed with bubble oxygenators. In one randomized trial
ugsley and colleagues7 showed a reduction in neuropsy-
hologic injury with a 40-m arterial line filter, a finding
hat both Aris and coworkersE57 and Sellman and associ-
tesE58 had been unable to demonstrate. In lieu of additional
tudies focused specifically on the association between the
se of arterial filters and neurologic injury, the association
etween embolic load and neuropsychologic outcome has
een demonstrated through reports by Pugsley and col-
eagues,7 Clark and coworkers,E59 and Stump and associ-
tes.E60
Arterial Filtration
Arterial line filters should be incorporated in the
CPB circuit to minimize the embolic load delivered to
the patient. (Class I, Level A).
aintenance of Euglycemia
s argued by Murkin,E61 there is both experimental and
linical evidence that hyperglycemia is associated with ex-
cerbation of neurologic injury, as well as a variety of other
dverse outcomes, including wound infection and mortality,
mong critically ill patients. McAlister and colleaguesE62
orrelated average blood glucose levels on the first postop-
rative day after CABG surgery with a variety of adverse
utcomes (stroke, myocardial infarction, septic complica-
ion, or death). For each 1-mmol/L increase above 6.1
mol/L (1 mmol  18 mg/dL), the risk of these outcomes
ncreased by 17%. In a prospective study of critically ill
atients, Finney and associatesE63 suggested that the control
f blood glucose levels, rather than insulin levels per se,
ccounts for apparent benefits in mortality. In a single-
enter study by Latham and coworkersE64 with an
ccompanying editorial by Dellinger,E65 the greatest risk for
urgical site infection among all patients undergoing car-
iothoracic surgery occurred among those with either post-
perative hyperglycemia (blood glucose levels 200 mg/
L) or undiagnosed diabetes. Estrada and associates24
eported on a historic cohort of 1574 patients undergoing
ABG between 1998 and 1999 within a single institution.
he authors found perioperative hyperglycemia to be asso-
iated with both longer postoperative length of stay and
ncreased hospitalization charges/costs among diabetic and
ondiabetic patients. t
The Journal of ThoracicFurnary and colleagues25 demonstrated, in a nonrandom-
zed, prospective interventional study of 4864 patients un-
ergoing cardiac procedures, that perioperative hyperglyce-
ia is directly associated with increased rates of death, deep
ternal wound infections, length of stay, and hospital costs.
he work from Furnary and colleagues,25,E66-E68 Estrada
nd associates,24 and McAlister and colleaguesE62 suggests
hat a target glucose range of less than 150 mg/dL is
avorable for maintaining euglycemia. Recent evidence by
arvalho and coworkersE69 suggests that maintenance of
ntraoperative blood glucose levels might be managed in
oth diabetic and nondiabetic patients with the use of an
ggressive insulin dosing strategy during cardiac surgery.
Ouattra and associates,E70 in an observational study of 200
onsecutive diabetic patients undergoing cardiac surgery, dem-
nstrated that poor intraoperative control of blood glucose
oncentrations was associated with an increased incidence of
n-hospital morbidity (including cardiovascular, infectious,
eurologic respiratory, neurologic, and renal). Two additional
bservational studies (Gandhi and coworkers26 and Doenst and
ssociates27), representing a combined 6689 patients undergo-
ng cardiac surgery, demonstrated a relationship between in-
raoperative hyperglycemia and mortality.
In a systematic review of the evidence authored by
arber and coworkers,E71 the position statement on inpa-
ient diabetes and metabolic control, sponsored by The
merican College of Endocrinology, the American Associ-
tion of Clinical Endocrinologists, and the cosponsoring
rganizations (including the Society of Thoracic Surgeons),
upports the need for early detection and aggressive man-
gement of hyperglycemia in the hospital setting for im-
roving patient outcomes.
Groban and associatesE72 identified increased blood sugar
s a routine accompaniment to CPB, reflecting in part the
ifficulty in effectively treating hyperglycemia, especially in
he presence of intense gluconeogenesis and insulin resistance,
uch as during CPB. As suggested by Murkin,E61 avoidance or
imitation of some of the following might effectively limit
yperglycemia with the expectation of enhanced neurologic
utcomes: (1) glucose containing intravenous, cardioplegic,
nd pump-priming solutions; (2) enhanced awareness and
reatment of catecholamine-induced hyperglycemia; and (3)
ore aggressive insulin dosing strategies.
Maintenance of Euglycemia
The clinical team should maintain perioperative
blood glucose concentration within an institution’s
normal clinical range in all patients, including non-
diabetic subjects. (Class I, Level B)
odified Extracorporeal Circuits
emodilution
urrently, the advancement of perfusion technology has ledo the development and use of condensed circuits and bio-
and Cardiovascular Surgery ● Volume 132, Number 2 287
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2assive surface modification. The goal of these efforts has
een to reduce the systemic inflammatory response syn-
rome (SIRS) while preserving platelet function and mini-
izing the need for allogeneic blood products.
Several large observational studies (DeFoe and col-
eagues,3 Habib and associates,28 Fang and coworkers,29
nd Karkouti and colleagues30) have identified an associa-
ion between nadir hematocrit (HCT) values and risk of
n-hospital mortality and other adverse events. DeFoe and
olleagues3 reported results from a multicenter study of
980 patients undergoing isolated CABG surgery. Patients
xperiencing a single HCT value of 19% or less during CPB
ad more than twice the mortality as patients with a nadir
CT value of 25%. Furthermore, the lowest HCT value
uring CPB was significantly associated with increased
ntraoperative or postoperative placement of an intra-aortic
alloon pump and return to CPB after attempted separation.
abib and associates28 retrospectively analyzed 5000 pa-
ients undergoing cardiac operations with CPB and found
hat stroke, myocardial infarction, low cardiac output, car-
iac arrest, renal failure, prolonged ventilation, pulmonary
dema, reoperation caused by bleeding, sepsis, and multi-
rgan failure were all significantly and systematically in-
reased as the lowest HCT value decreased to less than
2%. In a study of 2738 patients undergoing isolated
ABG, Fang and coworkers29 found an increased risk of
ostoperative death (odds ratio, 2.7) in patients with HCT
alues of 14% or less, and in a high-risk subgroup there was
n increased risk (odds ratio, 2.2) when the HCT value
uring CPB was less than 17%. Karkouti and colleagues30
xamined a series of 10,949 patients undergoing on-pump
ABGs and found that the risk of a perioperative stroke
ncreased 10% with each percentage decrease in nadir HCT
alue (95% confidence interval, 4%-18%; P  .002).
Additional studies (Karkouti and associatesE73 and
waminathan and coworkersE74) have also identified the
ssociation between nadir HCT values and renal injury.
arkouti and associatesE73 analyzed 9080 consecutive pa-
ients undergoing cardiac operations with CPB and found an
ndependent and nonlinear relationship between the nadir
CT value during CPB and acute renal failure, necessitating
ialysis support. Swaminathan and coworkers,E73 in a study
f 1404 patients undergoing primary elective CABG, found
oth a significant interaction between the lowest HCT value
uring CPB and body weight and between HCT value and
ostoperative creatinine increase level.
The observations listed above warrant the application of
echniques to reduce the incidence of low HCT values.
everal studies (McCusker and associates,E75 Cormack and
olleagues,E76 Beholz and coworkers,E77 van Boven and
ssociates,E78 Takai and colleagues,E79 and Shapira and
oworkersE80) have illustrated that a reduction in surface
rea–priming volume of the CPB circuit reduces the fre- b
88 The Journal of Thoracic and Cardiovascular Surgery ● Auguuency of low HCT values and subsequently reduces the
ncidence of allogeneic blood transfusions. Additionally, as
videnced by Rosengart and associates,E81 Balachandran
nd colleagues,E82 and Petry and coworkers,E83 the tech-
ique of retrograde autologous priming of the CPB circuit is
n effective means to decrease significantly hemodilution
nd the frequency of red cell transfusion during cardiac
perations. As documented by Speiss,E84 the untoward ef-
ects of allogeneic blood transfusions have been well doc-
mented in more than 3000 articles published in the medical
iterature. The adverse sequelae of transfusing red blood
ells include infection (Chelemer and colleaguesE85 and
eal-Noval and coworkersE86), renal injury and acute renal
ailure (Habib and coworkersE87), increased length of stay
Leal-Noval and coworkers,E86 Vamvakas and Carven,E88
nd Fransen and associatesE89), and mortality (Leal-Noval
nd coworkersE86 and Michalopoulos and associatesE90).
Kuduvalli and colleagues31 prospectively studied 3024
atients undergoing CABG and concluded that transfusion
ncreased both 30-day (1.9% vs 1.1%, P  .05) and 1-year
ortality (adjusted hazard ratio, 1.88; 95% confidence in-
erval, 1.23-3.00; P  .01).31 Engoren and coworkersE91
xamined the long-term effects of transfusion and found it
o be a significant predictor of mortality at 5 years.
Reduction of Hemodilution
Efforts should be made to reduce hemodilution,
including reduction of prime volume, to avoid subse-
quent allogeneic blood transfusion. (Class I, Level A)
ttenuation of the Inflammatory Response
he risk of SIRS and complement activation caused by CPB
as been well described by Kirklin and associatesE92 and
scione and coworkers.E93 Previous research by Ishikawa
nd colleagues,E94 Striggow and associates,E95 and Baufre-
on and coworkersE96 has reported the association between
he inflammatory processes and exacerbation of ischemic
rain injury by various mechanisms, including increased
apillary permeability, complement activation, neutrophil
ctivation, and protease-activated receptor upregulation.
lood contact with nonbiocompatible surfaces of the CPB
ircuit was implicated by Butler and associatesE5 as a cause
f the SIRS. A number of commercially available extracor-
oreal devices, including biocompatible surface coatings,
ondensed (miniaturized) extracorporeal circuits, and
eukocyte-depleting filters, have demonstrated a suppres-
ion of the inflammatory response to extracorporeal circu-
ation and improved outcomes. Administration of specific
nti-inflammatory pharmacologics has also been associated,
y Sedrakyan and coworkers32 and Asimakopoulos and
olleagues,E97 with decreased inflammatory processes and
mproved clinical outcomes.
The decrease in the incidence of SIRS with the use of
iocompatible surface technology is well documented by
st 2006
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Shann et al Cardiopulmonary Support and Physiologyaito and associates,E98 Videm and coworkers,E99 Fromes
nd colleagues,E100 and Moen and associates.E101 In addi-
ion, Defraigne and coworkersE102 and Rubens and col-
eaguesE103 documented platelet preservation with the use
f biocompatible surface additive–coated CPB circuits. Al-
hough several randomized clinical trials (Dickinson and
olleagues,E104 Mahoney and Lemole,33 McCarthy and co-
orkers,E105 Mongero and associates,E106 and Ranucci and
olleagues34) demonstrated improved outcomes with the
se of biocompatible circuits, one by Muehrcke and asso-
iatesE107 was unequivocal in its findings. Ranucci and
olleagues34 conducted a multicenter randomized trial eval-
ating the effect of heparin-coated circuits on clinical out-
omes among 886 patients undergoing cardiac operations.
eparin-coated circuits resulted in a shorter intensive care
nit (ICU) and postoperative length of stay and fewer “se-
erely impaired clinical outcomes” (defined as ICU length
f stay 5 days or death). McCarthy and coworkersE105
andomized 350 patients undergoing CABG reoperations
ith or without valve operations to receive either heparin-
oated or uncoated CPB circuits. The investigators’ proto-
ol included full-dose heparin, an open reservoir, and car-
iotomy suction. The percentage of major bleeding episodes
as significantly less with heparin-coated circuits. In a
rospective randomized study of 61 patients undergoing
lective cardiac surgery with CPB, Heyer and cowork-
rsE108 found that patients treated with heparin-bonded CPB
ircuits had less postoperative cognitive dysfunction. Fur-
hermore, a meta-analysis by MahoneyE109 has provided
vidence of clinical benefits and cost savings with the use of
eparin-bonded circuits. Finally, the combination of a con-
ensed circuit with biocompatible surface additive coating
as been associated (McCusker and associates,E75 Fromes
nd coworkers,E100 and Wiesenack and colleagues35) with
educed ventilator time, ICU and hospital length of stay, and
ransfusion requirements.
Attenuation of the Inflammatory Response
Reduction of circuit surface area and the use of
biocompatible surface–modified circuits might be use-
ful-effective at attenuating the systemic inflammatory
response to CPB and improving outcomes. (Class IIa,
Level B)
iscussion
e have made every effort to develop findings for perfusion
ractice that are grounded in evidence-based medicine. We
dopted a previously validated method for explicitly re-
iewing and grading the level and class of evidence as it
elates to neurologic injury, euglycemia, hemodilution, and
he inflammatory response. These findings will be updated
n a routine basis, including the addition of other practice
tems, to keep them contemporaneous with the peer-
The Journal of Thoraciceviewed medical literature and useful and pertinent to
racticing clinicians.
We gratefully acknowledge the contributions of the following
ndividuals: Robert Groom, Charles Krumholz, Alfred Stammers,
avid Stump, and Pamela Bagley.
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